Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice
Open Access
- 1 September 2004
- journal article
- review article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 89 (9), 877-880
- https://doi.org/10.1136/adc.2003.037341
Abstract
The function of cytotoxics is to damage cells, and it makes teleological sense for the body to expel them as soon after ingestion as possible. Ideally, from the body’s point of view, they should simply be avoided, and it is not surprising that the experience of chemotherapy induced nausea and vomiting (CINV) is powerfully aversive. Nausea and vomiting were once among the most intractable and unpleasant experiences of a child undergoing treatment for cancer.Keywords
This publication has 38 references indexed in Scilit:
- The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study GroupJournal of Clinical Oncology, 2003
- Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomitingCancer, 2003
- In vitro effects of combination chemotherapy on osteoblasts: implications for osteopenia in childhood malignancyBone, 2002
- Chemotherapy-Induced Nausea and VomitingClinical Journal of Oncology Nursing, 2002
- Delayed nausea and vomiting in children receiving antineoplasticsMedical and Pediatric Oncology, 2001
- COMPARISON OF TROPISETRON AND GRANISETRON IN THE CONTROL OF NAUSEA AND VOMITING IN CHILDREN RECEIVING COMBINED CANCER CHEMOTHERAPYPediatric Hematology and Oncology, 2001
- A COMPARISON OF ORAL ONDANSETRON SYRUP OR INTRAVENOUS ONDANSETRON LOADING DOSE REGIMENS GIVEN IN COMBINATION WITH DEXAMETHASONE FOR THE PREVENTION OF NAUSEA AND EMESIS IN PEDIATRIC AND ADOLESCENT PATIENTS RECEIVING MODERATELY/HIGHLY EMETOGENIC CHEMOTHERAPYPediatric Hematology and Oncology, 2000
- Safety, Tolerability, Antiemetic Efficacy, and Pharmacokinetics of Oral Dolasetron Mesylate in Pediatric Cancer Patients Receiving Moderately to Highly Emetogenic ChemotherapyJournal of Pediatric Hematology/Oncology, 1999
- Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.1999
- Delayed emesis following anticancer chemotherapy.Supportive Care in Cancer, 1998